Acute GVHD
| . | n . | Grade II-IV acute GVHD . | Grade III-IV acute GVHD . | ||||
|---|---|---|---|---|---|---|---|
| 100-d (95% CI) . | HR (95% CI)* . | P* . | 100-d (95% CI) . | HR (95% CI)* . | P* . | ||
| Donor type | |||||||
| MUD | 974 | 0.33 (0.30, 0.36) | Reference | .21 | 0.12 (0.10, 0.14) | Reference | .11 |
| Haplo | 487 | 0.32 (0.28, 0.37) | 1.13 (0.93, 1.38) | 0.14 (0.11, 0.17) | 1.30 (0.94, 1.80) | ||
| Recipient age, y | |||||||
| <30 | 579 | 0.36 (0.32, 0.40) | Reference | .068 | 0.15 (0.12, 0.18) | Reference | .07 |
| 30-39 | 281 | 0.32 (0.26, 0.37) | 0.85 (0.66, 1.10) | 0.13 (0.09, 0.17) | 0.82 (0.56, 1.22) | ||
| 40-54 | 350 | 0.33 (0.28, 0.38) | 0.86 (0.68, 1.09) | 0.10 (0.07, 0.14) | 0.63 (0.42, 0.94) | ||
| ≥55 | 251 | 0.27 (0.22, 0.33) | 0.69 (0.52, 0.92) | 0.10 (0.07, 0.14) | 0.61 (0.38, 0.98) | ||
| KPS† | |||||||
| 90-100 | 978 | 0.33 (0.30, 0.36) | Reference | 1.00 | 0.14 (0.11, 0.16) | Reference | .16 |
| ≤80 | 388 | 0.33 (0.28, 0.38) | 1.00 (0.81, 1.23) | 0.10 (0.07, 0.14) | 0.77 (0.53, 1.11) | ||
| ALL subtype | |||||||
| B-ALL | 1044 | 0.33 (0.30, 0.36) | Reference | .94 | 0.13 (0.11, 0.15) | Reference | .65 |
| T-ALL | 322 | 0.31 (0.26, 0.36) | 1.04 (0.82, 1.33) | 0.10 (0.07, 0.14) | 0.89 (0.58, 1.36) | ||
| Other | 95 | 0.35 (0.25, 0.45) | 1.03 (0.73, 1.43) | 0.15 (0.09, 0.24) | 1.19 (0.70, 2.02) | ||
| Months from diagnosis to HCT | |||||||
| ≤6 | 398 | 0.33 (0.28, 0.38) | Reference | .44 | 0.11 (0.08, 0.14) | Reference | .33 |
| >6-12 | 510 | 0.35 (0.30, 0.39) | 1.16 (0.91, 1.48) | 0.13 (0.10, 0.16) | 1.34 (0.90, 2.01) | ||
| >12 | 553 | 0.31 (0.27, 0.35) | 1.05 (0.78, 1.43) | 0.13 (0.11, 0.16) | 1.31 (0.79, 2.16) | ||
| HCT Comorbidity Index† | |||||||
| 0 | 147 | 0.35 (0.28, 0.43) | Reference | .90 | 0.14 (0.09, 0.20) | Reference | .68 |
| 1-2 | 92 | 0.37 (0.27, 0.47) | 1.10 (0.73, 1.66) | 0.16 (0.09, 0.24) | 1.21 (0.62, 2.36) | ||
| >2 | 94 | 0.41 (0.31, 0.51) | 1.07 (0.64, 1.78) | 0.12 (0.06, 0.19) | 0.88 (0.39, 2.00) | ||
| Donor age, y† | |||||||
| <30 | 342 | 0.38 (0.33, 0.43) | Reference | .42 | 0.14 (0.11, 0.18) | Reference | .90 |
| 30-49 | 443 | 0.34 (0.29, 0.38) | 0.86 (0.68, 1.09) | 0.13 (0.10, 0.16) | 0.92 (0.61, 1.37) | ||
| ≥50 | 127 | 0.35 (0.26, 0.43) | 0.97 (0.71, 1.34) | 0.14 (0.08, 0.20) | 0.92 (0.55, 1.54) | ||
| Female-to-male HCT† | |||||||
| No | 1172 | 0.33 (0.30, 0.36) | Reference | .80 | 0.13 (0.11, 0.15) | Reference | .37 |
| Yes | 262 | 0.34 (0.28, 0.40) | 1.03 (0.80, 1.32) | 0.11 (0.08, 0.16) | 0.82 (0.54, 1.26) | ||
| CMV serostatus† | |||||||
| D+/R− | 581 | 0.31 (0.28, 0.35) | Reference | .88 | 0.11 (0.09, 0.14) | Reference | .43 |
| D−/R− | 130 | 0.34 (0.26, 0.43) | 1.08 (0.78, 1.50) | 0.14 (0.09, 0.21) | 1.23 (0.71, 2.13) | ||
| D−/R− | 366 | 0.33 (0.28, 0.38) | 0.98 (0.78, 1.22) | 0.11 (0.08, 0.14) | 0.89 (0.60, 1.34) | ||
| D−/R− | 318 | 0.36 (0.31, 0.41) | 1.07 (0.84, 1.35) | 0.15 (0.11, 0.19) | 1.23 (0.84, 1.79) | ||
| Stem cell source | |||||||
| PB | 1056 | 0.35 (0.32, 0.38) | Reference | .001 | 0.13 (0.11, 0.15) | Reference | .14 |
| BM | 405 | 0.26 (0.22, 0.31) | 0.69 (0.55, 0.87) | 0.10 (0.08, 0.14) | 0.76 (0.53, 1.09) | ||
| Transplant period | |||||||
| 2005-2012 | 695 | 0.32 (0.29, 0.36) | Reference | .42 | 0.12 (0.09, 0.14) | Reference | .31 |
| 2013-2018 | 766 | 0.33 (0.30, 0.37) | 1.08 (0.90, 1.30) | 0.13 (0.11, 0.16) | 1.17 (0.87, 1.57) | ||
| . | n . | Grade II-IV acute GVHD . | Grade III-IV acute GVHD . | ||||
|---|---|---|---|---|---|---|---|
| 100-d (95% CI) . | HR (95% CI)* . | P* . | 100-d (95% CI) . | HR (95% CI)* . | P* . | ||
| Donor type | |||||||
| MUD | 974 | 0.33 (0.30, 0.36) | Reference | .21 | 0.12 (0.10, 0.14) | Reference | .11 |
| Haplo | 487 | 0.32 (0.28, 0.37) | 1.13 (0.93, 1.38) | 0.14 (0.11, 0.17) | 1.30 (0.94, 1.80) | ||
| Recipient age, y | |||||||
| <30 | 579 | 0.36 (0.32, 0.40) | Reference | .068 | 0.15 (0.12, 0.18) | Reference | .07 |
| 30-39 | 281 | 0.32 (0.26, 0.37) | 0.85 (0.66, 1.10) | 0.13 (0.09, 0.17) | 0.82 (0.56, 1.22) | ||
| 40-54 | 350 | 0.33 (0.28, 0.38) | 0.86 (0.68, 1.09) | 0.10 (0.07, 0.14) | 0.63 (0.42, 0.94) | ||
| ≥55 | 251 | 0.27 (0.22, 0.33) | 0.69 (0.52, 0.92) | 0.10 (0.07, 0.14) | 0.61 (0.38, 0.98) | ||
| KPS† | |||||||
| 90-100 | 978 | 0.33 (0.30, 0.36) | Reference | 1.00 | 0.14 (0.11, 0.16) | Reference | .16 |
| ≤80 | 388 | 0.33 (0.28, 0.38) | 1.00 (0.81, 1.23) | 0.10 (0.07, 0.14) | 0.77 (0.53, 1.11) | ||
| ALL subtype | |||||||
| B-ALL | 1044 | 0.33 (0.30, 0.36) | Reference | .94 | 0.13 (0.11, 0.15) | Reference | .65 |
| T-ALL | 322 | 0.31 (0.26, 0.36) | 1.04 (0.82, 1.33) | 0.10 (0.07, 0.14) | 0.89 (0.58, 1.36) | ||
| Other | 95 | 0.35 (0.25, 0.45) | 1.03 (0.73, 1.43) | 0.15 (0.09, 0.24) | 1.19 (0.70, 2.02) | ||
| Months from diagnosis to HCT | |||||||
| ≤6 | 398 | 0.33 (0.28, 0.38) | Reference | .44 | 0.11 (0.08, 0.14) | Reference | .33 |
| >6-12 | 510 | 0.35 (0.30, 0.39) | 1.16 (0.91, 1.48) | 0.13 (0.10, 0.16) | 1.34 (0.90, 2.01) | ||
| >12 | 553 | 0.31 (0.27, 0.35) | 1.05 (0.78, 1.43) | 0.13 (0.11, 0.16) | 1.31 (0.79, 2.16) | ||
| HCT Comorbidity Index† | |||||||
| 0 | 147 | 0.35 (0.28, 0.43) | Reference | .90 | 0.14 (0.09, 0.20) | Reference | .68 |
| 1-2 | 92 | 0.37 (0.27, 0.47) | 1.10 (0.73, 1.66) | 0.16 (0.09, 0.24) | 1.21 (0.62, 2.36) | ||
| >2 | 94 | 0.41 (0.31, 0.51) | 1.07 (0.64, 1.78) | 0.12 (0.06, 0.19) | 0.88 (0.39, 2.00) | ||
| Donor age, y† | |||||||
| <30 | 342 | 0.38 (0.33, 0.43) | Reference | .42 | 0.14 (0.11, 0.18) | Reference | .90 |
| 30-49 | 443 | 0.34 (0.29, 0.38) | 0.86 (0.68, 1.09) | 0.13 (0.10, 0.16) | 0.92 (0.61, 1.37) | ||
| ≥50 | 127 | 0.35 (0.26, 0.43) | 0.97 (0.71, 1.34) | 0.14 (0.08, 0.20) | 0.92 (0.55, 1.54) | ||
| Female-to-male HCT† | |||||||
| No | 1172 | 0.33 (0.30, 0.36) | Reference | .80 | 0.13 (0.11, 0.15) | Reference | .37 |
| Yes | 262 | 0.34 (0.28, 0.40) | 1.03 (0.80, 1.32) | 0.11 (0.08, 0.16) | 0.82 (0.54, 1.26) | ||
| CMV serostatus† | |||||||
| D+/R− | 581 | 0.31 (0.28, 0.35) | Reference | .88 | 0.11 (0.09, 0.14) | Reference | .43 |
| D−/R− | 130 | 0.34 (0.26, 0.43) | 1.08 (0.78, 1.50) | 0.14 (0.09, 0.21) | 1.23 (0.71, 2.13) | ||
| D−/R− | 366 | 0.33 (0.28, 0.38) | 0.98 (0.78, 1.22) | 0.11 (0.08, 0.14) | 0.89 (0.60, 1.34) | ||
| D−/R− | 318 | 0.36 (0.31, 0.41) | 1.07 (0.84, 1.35) | 0.15 (0.11, 0.19) | 1.23 (0.84, 1.79) | ||
| Stem cell source | |||||||
| PB | 1056 | 0.35 (0.32, 0.38) | Reference | .001 | 0.13 (0.11, 0.15) | Reference | .14 |
| BM | 405 | 0.26 (0.22, 0.31) | 0.69 (0.55, 0.87) | 0.10 (0.08, 0.14) | 0.76 (0.53, 1.09) | ||
| Transplant period | |||||||
| 2005-2012 | 695 | 0.32 (0.29, 0.36) | Reference | .42 | 0.12 (0.09, 0.14) | Reference | .31 |
| 2013-2018 | 766 | 0.33 (0.30, 0.37) | 1.08 (0.90, 1.30) | 0.13 (0.11, 0.16) | 1.17 (0.87, 1.57) | ||
Based on the multivariable proportional subdistribution hazards model for competing risks adjusted for age and stem cell source, and stratified by matching variables: sex, cytogenetic risk, Ph status, disease stage, and conditioning intensity. The robust sandwich covariance matrix estimate was used to adjust for within-center correlation.
Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.